Antidepressant Effects of Ketamine on Depression-like Behavior in Juvenile Mice after Neonatal Dexamethasone Exposure
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Objective: Pediatric depression is associated with significant functional impairment at school and at work. Recently, we reportedon depression-like behavior in juvenile mice neonatally exposed to dexamethasone (DEX) as a potential animal model for pediatricdepression. The N-methyl-D-aspartate (NMDA) receptor antagonist ketamine has promoted rapid and long-lasting antidepressanteffects in patients with treatment-resistant major depression. This study was conducted to examine whether ketaminehad antidepressant effects in juvenile mice after neonatal DEX exposure. Methods: A single dose (10 mg/kg) of ketamine or vehicle was injected into juvenile mice at days 29-32 after neonatal DEX(or saline) exposure (days 1-3). The sucrose preference test, tail suspension test, and forced swimming test were performed24, 40, and 46 hours, respectively, after injection of ketamine. Results: Ketamine (10 mg/kg) significantly improved depression-like behavior in DEX-treated juvenile mice. Conclusion: This finding suggests that ketamine confers antidepressant effects in an animal model of pediatric depression
Abstract
Objective: Pediatric depression is associated with significant functional impairment at school and at work. Recently, we reportedon depression-like behavior in juvenile mice neonatally exposed to dexamethasone (DEX) as a potential animal model for pediatricdepression. The N-methyl-D-aspartate (NMDA) receptor antagonist ketamine has promoted rapid and long-lasting antidepressanteffects in patients with treatment-resistant major depression. This study was conducted to examine whether ketaminehad antidepressant effects in juvenile mice after neonatal DEX exposure. Methods: A single dose (10 mg/kg) of ketamine or vehicle was injected into juvenile mice at days 29-32 after neonatal DEX(or saline) exposure (days 1-3). The sucrose preference test, tail suspension test, and forced swimming test were performed24, 40, and 46 hours, respectively, after injection of ketamine. Results: Ketamine (10 mg/kg) significantly improved depression-like behavior in DEX-treated juvenile mice. Conclusion: This finding suggests that ketamine confers antidepressant effects in an animal model of pediatric depression
참고문헌 (24)
- Fergusson DM, "Mental health, educational, and social role outcomes of adolescents with depression", Arch Gen Psychiatry, 59, pp.225~231 (2002)
- Cheung AH, "Pediatric depression: an evidence-based update on treatment interventions", Curr Psychiatry Rep, 15, pp.381~ (2013)
- McEwen BS., "Physiology and neurobiology of stress and adaptation: central role of the brain", Physiol Rev, 87, pp.873~904 (2007)
- Pittenger C, "Stress, depression, and neuroplasticity:a convergence of mechanisms", Neuropsychopharmacology, 33, pp.88~109 (2008)
- Li SX, "Role of the NMDA receptor in cognitive deficits, anxiety and depressive-like behavior in juvenile and adult mice after neonatal dexamethasone exposure", Neurobiol Dis, 62, pp.124~134 (2014)
- Javitt DC., "Glutamate as a therapeutic target in psychiatric disorders", Mol Psychiatry, 9, pp.984~997 (2004)
- Skolnick P, "Glutamate-based antidepressants:20 years on", Trends Pharmacol Sci, 30, pp.563~569 (2009)
- Hashimoto K, "Increased levels of glutamate in brains from patients with mood disorders", Biol Psychiatry, 62, pp.1310~1316 (2007)
- Hashimoto K., "Emerging role of glutamate in the pathophysiology of major depressive disorder", Brain Res Rev, 61, pp.105~123 (2009)
- Hashimoto K., "The role of glutamate on the action of antidepressants", Prog Neuropsychopharmacol Biol Psychiatry, 35, pp.1558~1568 (2011)
- Hashimoto K., "Therapeutic implications for NMDA receptors in mood disorders", Expert Rev Neurother, 13, pp.735~737 (2013)
- Zarate C Jr, "Glutamatergic modulators:the future of treating mood disorders?", Harv Rev Psychiatry, 18, pp.293~303 (2010)
- Tokita K, "Roles of glutamate signaling in preclinical and", or mechanistic models of depression, 2012, pp.100, 688~704
- Berman RM, "Antidepressant effects of ketamine in depressed patients", Biol Psychiatry, 47, pp.351~354 (2000)
- Zarate CA Jr, "A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression", Arch Gen Psychiatry, 63, pp.856~864 (2006)
- Krystal JH, "Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond", Biol Psychiatry, 73, pp.1133~1141 (2013)
- Aan Het Rot M, "Ketamine for depression: where do we go from here?", Biol Psychiatry, 72, pp.537~547 (2012)
- Domino EF., "Taming the ketamine tiger. 1965", Anesthesiology, 113, pp.678~684 (2010)
- Duman RS, "Signaling pathways underlying the rapid antidepressant actions of ketamine", Neuropharmacology, 62, pp.35~41 (2012)
- Zunszain PA, "Ketamine: synaptogenesis, immunomodulation and glycogen synthase kinase-3 as underlying mechanisms of its antidepressant properties", Mol Psychiatry, 18, pp.1236~1241 (2013)
- Nestler EJ, "Preclinical models: status of basic research in depression", Biol Psychiatry, 52, pp.503~528 (2002)
- Pariante CM, "Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment", Biol Psychiatry, 49, pp.391~404 (2001)
- Willner P., "Chronic mild stress (CMS) revisited: consistency and behavioural-neurobiological concordance in the effects of CMS", Neuropsychobiology, 52, pp.90~110 (2005)
- Ma XC, "Wu J", PLoS One, 8, pp.e56053~ (2013)